Marissa E Sakoda1, Pariya L Fazeli, Ronald J Ellis, Dilip V Jeste, Igor Grant, Scott L Letendre, David J Moore. 1. *Department of School of Medicine, John A. Burns School of Medicine, University of Hawaii Honolulu, HI; Departments of †Psychiatry; ‡Neurosciences, University of California, San Diego, San Diego, CA; §Stein Institute for Research on Aging, University of California, San Diego, San Diego, CA; and ‖Department of Medicine, University of California, San Diego, San Diego, CA.
Abstract
OBJECTIVE: The study aims to determine whether cystatin C is associated with HIV disease and HIV-associated neurocognitive impairment (NCI). METHODS: Participants included 124 (HIV+ n = 77; HIV- n = 47) older adults (age ≥ 50 years) examined at the University of California, San Diego HIV Neurobehavioral Research Program. Cystatin C, a biomarker of kidney functioning that has been linked to poor health outcomes, was measured in blood. Participants completed a comprehensive neurocognitive assessment that was used to define both global and domain NCI. RESULTS: The HIV+ group had significantly higher cystatin C concentrations than the HIV- group (d = 0.79 P < 0.001). Among HIV+ participants, those with NCI had higher cystatin C concentrations than those without NCI (d = 0.42, P = 0.055), particularly among participants taking tenofovir (d = 0.78, P = 0.004). A receiver-operator characteristic curve identified that cystatin C levels ≥0.75 mg/L were associated with NCI in the HIV+ group. Using this binary variable and including relevant covariates, multivariate modeling confirmed that NCI was associated with higher cystatin C levels (OR = 3.0; P = 0.03). CONCLUSIONS: Our results confirm that HIV+ older adults have higher cystatin C than HIV- older adults and further identify that cystatin C may be associated with NCI in this population, particularly if they use tenofovir. This blood biomarker may be a useful clinical tool to identify older HIV+ persons at greater risk for cognitive decline.
OBJECTIVE: The study aims to determine whether cystatin C is associated with HIV disease and HIV-associated neurocognitive impairment (NCI). METHODS:Participants included 124 (HIV+ n = 77; HIV- n = 47) older adults (age ≥ 50 years) examined at the University of California, San Diego HIV Neurobehavioral Research Program. Cystatin C, a biomarker of kidney functioning that has been linked to poor health outcomes, was measured in blood. Participants completed a comprehensive neurocognitive assessment that was used to define both global and domain NCI. RESULTS: The HIV+ group had significantly higher cystatin C concentrations than the HIV- group (d = 0.79 P < 0.001). Among HIV+ participants, those with NCI had higher cystatin C concentrations than those without NCI (d = 0.42, P = 0.055), particularly among participants taking tenofovir (d = 0.78, P = 0.004). A receiver-operator characteristic curve identified that cystatin C levels ≥0.75 mg/L were associated with NCI in the HIV+ group. Using this binary variable and including relevant covariates, multivariate modeling confirmed that NCI was associated with higher cystatin C levels (OR = 3.0; P = 0.03). CONCLUSIONS: Our results confirm that HIV+ older adults have higher cystatin C than HIV- older adults and further identify that cystatin C may be associated with NCI in this population, particularly if they use tenofovir. This blood biomarker may be a useful clinical tool to identify older HIV+ persons at greater risk for cognitive decline.
Authors: Samir K Gupta; Joseph A Eustace; Jonathan A Winston; Ivy I Boydstun; Tejinder S Ahuja; Rudolph A Rodriguez; Karen T Tashima; Michelle Roland; Nora Franceschini; Frank J Palella; Jeffrey L Lennox; Paul E Klotman; Sharon A Nachman; Stephen D Hall; Lynda A Szczech Journal: Clin Infect Dis Date: 2005-04-22 Impact factor: 9.079
Authors: R J Ellis; R Deutsch; R K Heaton; T D Marcotte; J A McCutchan; J A Nelson; I Abramson; L J Thal; J H Atkinson; M R Wallace; I Grant Journal: Arch Neurol Date: 1997-04
Authors: William R Swindell; Steven R Cummings; Jason L Sanders; Paolo Caserotti; Caterina Rosano; Suzanne Satterfield; Elsa S Strotmeyer; Tamara B Harris; Eleanor M Simonsick; Peggy M Cawthon Journal: Rejuvenation Res Date: 2012-05-18 Impact factor: 4.663
Authors: Anne M Murray; Joshua I Barzilay; James F Lovato; Jeff D Williamson; Michael E Miller; Santica Marcovina; Lenore J Launer Journal: Diabetes Care Date: 2011-06-29 Impact factor: 19.112
Authors: Petronela Ancuta; Anupa Kamat; Kevin J Kunstman; Eun-Young Kim; Patrick Autissier; Alysse Wurcel; Tauheed Zaman; David Stone; Megan Mefford; Susan Morgello; Elyse J Singer; Steven M Wolinsky; Dana Gabuzda Journal: PLoS One Date: 2008-06-25 Impact factor: 3.240
Authors: Robert C Kalayjian; Kevin R Robertson; Jeffrey M Albert; Carl J Fichtenbaum; Todd T Brown; Babafemi O Taiwo Journal: J Acquir Immune Defic Syndr Date: 2019-06-01 Impact factor: 3.731
Authors: Violet Awori; Gertrude Nakigozi; Alice Kisakye; James Batte; Aggrey Anok; Richard Mayanja; Noeline Nakasujja; Kevin R Robertson; Ronald H Gray; Maria J Wawer; Ned Sacktor; Deanna Saylor Journal: J Neurovirol Date: 2019-11-12 Impact factor: 2.643